000165986 001__ 165986
000165986 005__ 20240229133516.0
000165986 0247_ $$2doi$$a10.1007/s00401-020-02243-6
000165986 0247_ $$2pmid$$apmid:33216206
000165986 0247_ $$2ISSN$$a0001-6322
000165986 0247_ $$2ISSN$$a1432-0533
000165986 0247_ $$2altmetric$$aaltmetric:94654163
000165986 037__ $$aDKFZ-2020-02525
000165986 041__ $$aeng
000165986 082__ $$a610
000165986 1001_ $$0P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c$$aSuwala, Abigail Kora$$b0$$eFirst author$$udkfz
000165986 245__ $$aPrimary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
000165986 260__ $$aHeidelberg$$bSpringer$$c2021
000165986 3367_ $$2DRIVER$$aarticle
000165986 3367_ $$2DataCite$$aOutput Types/Journal article
000165986 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1611323380_16310
000165986 3367_ $$2BibTeX$$aARTICLE
000165986 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000165986 3367_ $$00$$2EndNote$$aJournal Article
000165986 500__ $$a#EA:B300#LA:B300#2021 Jan;141(1):85-100
000165986 520__ $$aDiffuse IDH-mutant astrocytoma mostly occurs in adults and carries a favorable prognosis compared to IDH-wildtype malignant gliomas. Acquired mismatch repair deficiency is known to occur in recurrent IDH-mutant gliomas as resistance mechanism towards alkylating chemotherapy. In this multi-institutional study, we report a novel epigenetic group of 32 IDH-mutant gliomas with proven or suspected hereditary mismatch repair deficiency. None of the tumors exhibited a combined 1p/19q deletion. These primary mismatch repair-deficient IDH-mutant astrocytomas (PMMRDIA) were histologically high-grade and were mainly found in children, adolescents and young adults (median age 14 years). Mismatch repair deficiency syndromes (Lynch or Constitutional Mismatch Repair Deficiency Syndrom (CMMRD)) were clinically diagnosed and/or germline mutations in DNA mismatch repair genes (MLH1, MSH6, MSH2) were found in all cases, except one case with a family and personal history of colon cancer and another case with MSH6-deficiency available only as recurrent tumor. Loss of at least one of the mismatch repair proteins was detected via immunohistochemistry in all, but one case analyzed. Tumors displayed a hypermutant genotype and microsatellite instability was present in more than half of the sequenced cases. Integrated somatic mutational and chromosomal copy number analyses showed frequent inactivation of TP53, RB1 and activation of RTK/PI3K/AKT pathways. In contrast to the majority of IDH-mutant gliomas, more than 60% of the samples in our cohort presented with an unmethylated MGMT promoter. While the rate of immuno-histochemical ATRX loss was reduced, variants of unknown significance were more frequently detected possibly indicating a higher frequency of ATRX inactivation by protein malfunction. Compared to reference cohorts of other IDH-mutant gliomas, primary mismatch repair-deficient IDH-mutant astrocytomas have by far the worst clinical outcome with a median survival of only 15 months irrespective of histological or molecular features. The findings reveal a so far unknown entity of IDH-mutant astrocytoma with high prognostic relevance. Diagnosis can be established by aligning with the characteristic DNA methylation profile, by DNA-sequencing-based proof of mismatch repair deficiency or immunohistochemically demonstrating loss-of-mismatch repair proteins.
000165986 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000165986 588__ $$aDataset connected to CrossRef, PubMed,
000165986 7001_ $$0P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aStichel, Damian$$b1$$udkfz
000165986 7001_ $$0P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aSchrimpf, Daniel$$b2$$udkfz
000165986 7001_ $$0P:(DE-He78)028ee60cca729028708496826f077b58$$aKloor, Matthias$$b3$$udkfz
000165986 7001_ $$0P:(DE-He78)32977c5abc127b0373ece54294a41f63$$aWefers, Annika K$$b4$$udkfz
000165986 7001_ $$0P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2$$aReinhardt, Annekathrin$$b5$$udkfz
000165986 7001_ $$aMaas, Sybren L N$$b6
000165986 7001_ $$aKratz, Christian P$$b7
000165986 7001_ $$0P:(DE-He78)db2e8cf0dd8fa826896839ffee4b1411$$aSchweizer, Leonille$$b8$$udkfz
000165986 7001_ $$aHasselblatt, Martin$$b9
000165986 7001_ $$aSnuderl, Matija$$b10
000165986 7001_ $$aAbedalthagafi, Malak Sameer J$$b11
000165986 7001_ $$aAbdullaev, Zied$$b12
000165986 7001_ $$aMonoranu, Camelia M$$b13
000165986 7001_ $$aBergmann, Markus$$b14
000165986 7001_ $$aPekrun, Arnulf$$b15
000165986 7001_ $$aFreyschlag, Christian$$b16
000165986 7001_ $$aAronica, Eleonora$$b17
000165986 7001_ $$aKramm, Christof M$$b18
000165986 7001_ $$0P:(DE-He78)8126cfb1cc3fa7fa8fd5c20410c6d863$$aHinz, Felix$$b19$$udkfz
000165986 7001_ $$0P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aSievers, Philipp$$b20$$udkfz
000165986 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b21$$udkfz
000165986 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b22$$udkfz
000165986 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b23$$udkfz
000165986 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b24$$udkfz
000165986 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David T W$$b25$$udkfz
000165986 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b26$$udkfz
000165986 7001_ $$aUnterberg, Andreas$$b27
000165986 7001_ $$aHartmann, Christian$$b28
000165986 7001_ $$aDodgshun, Andrew$$b29
000165986 7001_ $$aTabori, Uri$$b30
000165986 7001_ $$aWesseling, Pieter$$b31
000165986 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b32$$udkfz
000165986 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b33$$udkfz
000165986 7001_ $$0P:(DE-He78)d5149ffd74f42a2fa87a086d66645aaa$$aReuß, David$$b34$$eLast author$$udkfz
000165986 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-020-02243-6$$n1$$p85-100$$tActa neuropathologica$$v141$$x1432-0533$$y2021
000165986 909CO $$ooai:inrepo02.dkfz.de:165986$$pVDB
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)028ee60cca729028708496826f077b58$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)32977c5abc127b0373ece54294a41f63$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)db2e8cf0dd8fa826896839ffee4b1411$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8126cfb1cc3fa7fa8fd5c20410c6d863$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b25$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b26$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b32$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b33$$kDKFZ
000165986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d5149ffd74f42a2fa87a086d66645aaa$$aDeutsches Krebsforschungszentrum$$b34$$kDKFZ
000165986 9130_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000165986 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000165986 9141_ $$y2021
000165986 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-08-23$$wger
000165986 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2020-08-23$$wger
000165986 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-23
000165986 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-23
000165986 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-23
000165986 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-08-23
000165986 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-23
000165986 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-08-23
000165986 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-23
000165986 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-23
000165986 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-23
000165986 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2018$$d2020-08-23
000165986 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-08-23
000165986 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-08-23
000165986 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bACTA NEUROPATHOL : 2018$$d2020-08-23
000165986 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000165986 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000165986 9201_ $$0I:(DE-He78)F210-20160331$$kF210$$lAngewandte Tumorbiologie$$x2
000165986 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK BE zentral$$x3
000165986 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x4
000165986 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPediatric Glioma$$x5
000165986 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x6
000165986 980__ $$ajournal
000165986 980__ $$aVDB
000165986 980__ $$aI:(DE-He78)B300-20160331
000165986 980__ $$aI:(DE-He78)HD01-20160331
000165986 980__ $$aI:(DE-He78)F210-20160331
000165986 980__ $$aI:(DE-He78)BE01-20160331
000165986 980__ $$aI:(DE-He78)B062-20160331
000165986 980__ $$aI:(DE-He78)B360-20160331
000165986 980__ $$aI:(DE-He78)B320-20160331
000165986 980__ $$aUNRESTRICTED